Advances in the validation of chromatographic processes

BioPharm International

Volumn , Issue SUPPL., 2007, Pages 20-25

  Sofer, Gail ^a   Ahnfelt, Mattias ^a  

^a GE Healthcare Life Sciences

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PLASMID DNA;

ANALYTIC METHOD; BIOTECHNOLOGY; CHROMATOGRAPHY; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; EQUIPMENT; EXPERIMENTAL DESIGN; LIFE CYCLE ASSESSMENT; LIFESPAN; PROCESS DEVELOPMENT; QUALITY CONTROL; REVIEW; RISK MANAGEMENT; SCALE UP; STORAGE; VALIDATION PROCESS;

EID: 33847126075     PISSN: 1542166X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. International Conference on Harmonization. Q8, pharmaceutical development. Geneva, Switzerland; 2005.
2. International Conference on Harmonization. Q9, quality risk management. Geneva, Switzerland; 2005.
3. Seely JE, Seely RJ. A rational, step wise approach to process characterization. BioPharm Int. 2003;16(8):24-34.
4. Murtagh J. Development of a bio-derived drug. Contract pharma. 2006;8(3):70-75.
5. Mollah AH. Application of FMEA for process risk assessment. 2005;3(10):12-22.
6. Brorson K, et al. Impact of cell culture process changes on endogenous retroviral expression. Biotechnol. bioeng. 2002;80(3):257-67.
7. Application Note 28-4078-17 AA, Capto S cation exchanger for post-protein A purification of monoclonal antibodies. Chalfont St. Giles, UK; 2006.
8. US Food and Drug Administration. Guidance for industry. General principles of process validation. Rockville, MD; May 2006.
9. Rathore A. Efficiency measurements for chromatography columns. BioPharm Int. 2005;18(8):58-64.
10. US Food and Drug Administration. Therapeutic compliance guide. 7341.001.
11. Norling L, et al. Impact of multiple re-use of anion-exchange chromatography media on virus removal. J Chrom A. 2005;1069(1):79-89.
12. Brorson K, et al. Identification of protein A media performance attributes that can be monitored as surrogates for retrovirus clearance during extended re-use. J Chrom A. 2003;989(1):153-163.
13. International Conference on Harmonization. Q 5A, viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Geneva, Switzerland; 1997.